<DOC>
	<DOCNO>NCT00705861</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety SK3530 erectile dysfunction Patients Diabetes Mellitus .</brief_summary>
	<brief_title>Study Assess Efficacy Safety SK3530 Erectile Dysfunction Patients With Diabetes Mellitus</brief_title>
	<detailed_description>SK3530 potent selective phosphdiesterase type 5 ( PDE 5 ) inhibitor develop treatment erectile dysfunction ( ED ) . Since ED common men Diabetes Mellitus , important determine efficacy safety SK3530 erectile dysfunction Patients Diabetes Mellitus .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Erectile Dysfunction</mesh_term>
	<criteria>clinical diagnosis type 1 type 2 diabetes . Score 25 IIEF EF domain 4 week treatment runin period . Failure rate 50 % sexual attempt 4 4 week treatment runin period . Lab abnormality . Uncontrolled diabetic mellitus ( HbA1c &gt; 12 % ) . High low blood pressure , orthostatic hypotension . Hyper hypothyroidism .</criteria>
	<gender>Male</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>Erectile dysfunction</keyword>
	<keyword>Diabetes Mellitus</keyword>
	<keyword>SK3530</keyword>
</DOC>